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Abstract
Graphene nanomaterials have attracted wide attention in recent years on their application to state-
of-the-art technology due to their outstanding physical properties. On the other hand, the 
nanotoxicity of graphene materials also has rapidly become a serious concern especially in 
occupational health. Graphene materials inevitably could become airborne in the workplace during 
manufacturing processes. The inhalation and subsequent deposition of graphene nanoparticles in 
the human respiratory tract could potentially result in adverse health effects to exposed workers. 
Therefore, investigating the deposition of graphene nanoparticles in the human airways is 
considered essential for an integral graphene occupational health study. For this reason, this study 
carried out a series of airway replica deposition experiments to obtain original data of graphene 
nanoparticle airway deposition. In this study, size classified graphene nanoparticles were delivered 
into human airway replicas (both nasal and oral-to-lung airways). The deposition fraction and 
efficiency of graphene nanoparticle in the airway were obtained by a novel experimental approach. 
The experimental results acquired showed that the fractional deposition of graphene nanoparticles 
in airway sections studied were all less than 4%, and the deposition efficiencies in each airway 
section were generally lower than 0.03. These results implies that the majority of the graphene 
nanoparticles inhaled into the human respiratory tract could easily penetrate through the head 
airways as well as the upper part of the tracheobronchial airways and then transit down to the 
lower lung airways, where undesired biological responses might be induced.
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 INTRODUCTION
Graphene is a one-atom-thick, platelet-like nanomaterial constructed by pure carbon atoms 
first produced only a decade ago,(1) whereas it has drawn substantial scientific attention and 
technology interest today. The distinctive physical characteristics of graphene in terms of 
mechanical strength, physical elasticity, thermal conductivity and electrical property have 
made graphene a unique material for application in various high-tech products in areas of 
electronics, energy storage, and composite materials.(2) Besides, graphene also has proven to 
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possess a great potential for biomedical and biotechnology application such as drug delivery, 
biosensing, and tissue engineering.(3) Because of these potential and valuable applications, 
graphene has become one of the intensively studied nanomaterials both in industry and 
academia.(4,5)
Despite its promising future, the nanotoxicity of graphene has also rapidly become a serious 
concern. According to published toxicity studies on graphene family materials (graphene 
family materials includes graphene nanosheets, few-layer graphene, graphene oxide, etc.),(6) 
mice administrated with graphene family materials could induce lung granuloma 
formation,(7) inflammation cell infiltration, pulmonary edema,(8) severe and persistent lung 
injury,(9) and acute pulmonary inflammatory and frustrated alveolar phagocytosis.(10) Some 
in vitro cell culture studies also indicated that graphene family materials could induce 
cytotoxic effects in human neuronal cells,(11) cause viability decreasing and apoptosis in 
human lung cells,(12) and show cell sensitivity and concentration-dependent cytotoxicity in 
alveolar basal epithelial cells.(13) Based on these research results, it would be safe to assume 
that the inhalation and deposition of graphene nanoparticles in the human respiratory tract 
might cause possible adverse biological response.
Due to the fact that graphene materials inevitably could become airborne during product 
harvesting, handling, and reactor cleaning processes in related workplaces,(14) workers and 
researchers in graphene associated manufactories and laboratories could involuntarily inhale 
graphene nanoparticles. The consequent deposition of graphene nanoparticles in workers’ 
respiratory tract could potentially pose adverse health effects to them. Thus, the risk of 
worker and researcher exposure to graphene nanoparticles in workplaces should be 
considered an essential occupational health issue in today's nanotechnology era. The 
investigation of the graphene nanoparticles airway deposition, therefore, should be the 
indispensable component of an integral graphene occupational health study.
However, because the dimension of the graphene nanoparticle is extremely small, it is 
infeasible to apply conventional airway deposition methods on graphene nanoparticles for 
conducting airway replica deposition studies. The conventional methods for particle airway 
replica deposition study involves either radioactive or fluorescent labeled test 
particles.(15, 16, 17) These experimental methods are considered technically difficult to apply 
on graphene nanomaterials not only because of the required radioactive facilities, but also 
due to the measurement limitation for fluorescent tagged nanoparticles. Therefore, there is a 
need for an alternative experimental method to carry out airway replica deposition 
experiments for nanoparticles. For this reason, a novel experimental approach has been 
developed in our laboratory and was employed previously in our laboratory for two airway 
replica deposition studies using carbon nanotubes.(18, 19) A great number of quality airway 
deposition data were acquired by using this experimental approach. In this study, the novel 
experimental approach was applied on graphene nanoparticles to obtain some original 
airway replica deposition data. This is the first time in literature that the graphene 
nanoparticle was employed for airway replica deposition experiments. The experimental 
data obtained from this study is believed to be valuable for assessing the risk of the worker 
exposure to airborne graphene nanomaterials in related occupational settings, considering 
the deposition portion shown in the upper airways can directly indicate the portion of the 
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inhaled graphene nanoparticles that entered the lower airways. In addition, the deposition 
data acquired from this study can also be used for verifying numerical models newly 
developed for nanoparticle airway dosimetry estimation.
 METHOD
The novel experimental approach, briefly speaking, is to generate size classified 
nanoparticles in preselected diameters and then deliver them into a human airway replica 
(and trimmed ones). The fractional deposition in each airway section is the principal data to 
be obtained. To achieve this goal, the graphene nanomaterial was aerosolized, size classified, 
and then delivered into the airway replica for measuring the needed data as explained by the 
following procedures.
 Graphene Nanoparticle Generation
The graphene nanomaterial used for generating graphene nanoparticles was purchased from 
Cheap Tube Inc. (Brattleboro, VT, USA). This graphene nanomaterial was in grad 3, which 
contained 97% purity, 2 μm in platelet diameter, and 600-750 m2/g surface area. Figure 1 
shows the morphology of the graphene nanomaterial under a transmission electron 
microscope (TEM). As can be seen, the graphene nanomaterial was severely agglomerated. 
Graphene in crumpled, crushed, and platelet-like shapes were found in the bulk material. To 
aerosolize the generate nanomaterial for the deposition study, an electrospray (Model 3480, 
TSI Inc., Shoreview, MN, USA) was employed. The electrospray is a widely applied 
aerosolization device capable of generating airborne nanomaterials with uniform size and 
shape. This electrospray has been used in a variety of studies for generating nanoparticles, 
including carbon nanotubes and engineered nanomaterials.(20, 21) To use electrospray for 
generating graphene nanoparticles, graphene suspension was prepared by adding 90 mg 
graphene material into 20 ml ethanol alcohol with 5 μl ammonium acetate as a buffer 
solution. The graphene suspension was treated with ultrasonicator for 10 minutes each time 
before being added into the electrospray for generating graphene nanoparticles. The 
capillary used for transporting graphene suspension in the electrospray was made of silica 
with ID of 100 μm and OD of 360 μm (Polymicro Technologies, Phoenix, AZ). When 
operating the electrospray, 4.0 psi differential pressure was set on the electrospray to push 
graphene suspension from the sample vial through the capillary tube to the opening end of 
the capillary. A high voltage of 2.3 kV was added to the capillary, which generated an 
electrical field at the end of the capillary and pulled the graphene suspension from the 
capillary to form tiny droplets. A mix of filtered air and CO2 (0.1 L/min each) was then used 
to evaporate ethanol in the droplets and have only graphene nanoparticles remaining in the 
air. Before leaving the outlet of the electrospray, the graphene nanoparticles were neutralized 
by a Po-210 ionizer.
 Graphene Nanoparticle Characterization
The graphene nanoparticles generated were then delivered to a differential mobility analyzer 
(DMA, Model 3071A, TSI Inc., Shoreview, MN) for size classification. The principle of the 
DMA is to use the balance between the electrostatic force and the air drag force acting on 
the nanoparticles to size classify them from polydisperse to monodisperse according to the 
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electrical mobility diameter (dB) of the nanoparticles. The graphene nanoparticle size 
classification was conducted by delivering graphene nanoparticles of 1 L/min into the DMA, 
and the DMA was set with parameters (sheath flow of 10 L/min and assigned voltages) to 
size classify the graphene nanoparticles based on their dB. The preselected classification 
diameters for the graphene nanoparticles for the deposition study were 51, 101, and 215 nm. 
To ensure the size classified graphene nanoparticles having the designated classification 
diameter, a sequential mobility particle sizer (SMPS, GRIMM Aerosol Technik GmbH & 
Co., Germany) was used to monitor the size distribution of the classified graphene 
nanoparticles. Samples of the size classified graphene nanoparticles were also collected on 
TEM grids with a point-to-plane electrostatic precipitator (In-Tox Products, Albuquerque, 
NM) for morphology analysis. The morphology analysis was conducted by a JEOL 2010 
TEM (JEOL Ltd., Tokyo, Japan). Pictures of graphene nanoparticles were taken for each 
classification diameter during the morphology analysis. Figure 2 shows the morphology of 
the size classified graphene nanoparticles inspected by the TEM, the size distribution 
measured by the SMPS, and the area equivalent diameter calculated based on the particle 
envelop area measured from corresponding particle TEM pictures.
To obtain the aerodynamic diameter (dae) for the size classified graphene nanoparticles, an 
aerosol particle mass analyzer (APM, Kanomax USA, Inc., Andover, NJ) was used for this 
purpose. The main body of the APM consists of two wired co-axis metal cylinders, and the 
nanoparticles were introduced inbetween the gap of the two cylinders while they were 
spinning. The principle of the APM is to utilize the balance between the electrostatic force 
(by varying the cylinder voltage) and centrifugal force (by varying the cylinder r.p.m) acting 
on the nanoparticle while passing through the gap of the two spinning cylinders to acquire 
the mass information of the nanoparticle of interest. By using the APM together with the 
DMA to form a DMA-APM tandem setup,(22, 23) and by using PSL particles with known 
size and density as reference particles, the aerodynamic diameter of the size classified 
graphene nanoparticles can then be estimated.
 Human Airway Replicas
In this study, the airway deposition experiments were conducted with both nasal and oral-to-
lung airway replicas. For the nasal airway deposition study, a nasal airway replica 
constructed with 77 acrylic plates (1.5 mm in thickness for each plate) was used. This nasal 
airway replica was made based on a set of in vivo head MRI scans of a male adult. This 
nasal airway replica consists of detailed nasal airway structures including the nostril, 
vestibule, nasal valve, turbinate, and nasopharynx. The airway geometry and the air flow 
field in this nasal airway replica have already been well studied,(24, 25) and this nasal airway 
replica has been employed in our laboratory for a number of airway deposition studies using 
spherical particles, fiber aerosols, and carbon nanotubes.(18, 26, 27) Deposition results 
obtained have demonstrated that this nasal airway replica is able to provide reliable 
experimental data for aerosol nasal airway deposition study. Figure 3 shows the nasal airway 
replica used in this study with sample acrylic plates in certain airway sections. For the oral-
to-lung airway deposition study, a human respiratory tract replica made of conductive 
silicone rubber (KE-4576, Shin-Etsu Chemical Co., Ltd., Tokyo, Japan) was used. The 
original production mold of this human respiratory tract replica was made from a 
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cadaver.(28) This human airway replica consists of an oral cavity, pharynx, larynx, and 
tracheobronchial airways down to part of the 4th lung generation. The geometry and 
dimension of this oral-to-lung airway replica also has been well studied.(29) This oral-to-
lung airway replica also has been frequently used in our laboratory for aerosol airway 
deposition studies and numerous representative data were acquired.(17, 19, 30, 31) Figure 4 
shows a physical model and illustrates the airway structure of the oral-to-lung airway 
replica. In this study, due to the design of the experimental approach used for conducting the 
airway deposition study, several identical oral-to-lung airway replicas were trimmed based 
on the human lung structure physiology to have only certain lung generations remain on the 
replica. All the trimmed airway replicas used in this study are also demonstrated in Figure 4. 
It is worth mentioning that, when preparing the nasal airway or the oral-to-lung airway 
replica for the deposition experiment, silicon oil (550 Fluid, Dow Corning Co., Midland, 
MI) was applied onto the inside surface of the replica (dripped overnight) to simulate the wet 
surface nature of the real human airways.
 Graphene Nanoparticle Airway Deposition Estimation
Figures 5 and 6 show the experimental setups of the graphene nanoparticle airway 
deposition studies for the nasal airway and oral-to-lung airway respectively. As can be seen, 
the DMA size classified graphene nanoparticles were delivered straight into the airway 
replica for the deposition experiments. The SMPS was used in the experiment for measuring 
the average concentrations, C, of the graphene nanoparticle in the airway replica. When 
measuring the average concentration, the SMPS output channels were rearranged to have 
only one channel that matches the designated classification diameter (the channel showing 
the peak concentration) to show on the SMPS monitor. In this way, it permits the tracking of 
the concentration variation of the size classified graphene nanoparticle over a period of time. 
The average concentration of graphene nanoparticle was measured in a pair (Cinlet, Coutlet) at 
both the inlet and outlet of the airway replica by using a two-way valve. For the nasal airway 
replica, since there is only one airway section (the entire nasal airway) and one outlet 
(nasopharynx) on the replica, only one pair of the graphene nanoparticle concentration was 
required to determine the airway deposition. However, for the oral-to-lung airway replica, 
there are a total of ten airway sections in replica. Therefore, several pairs of concentration 
were needed to determine the deposition in different airway sections. When all of the 
required concentration pairs were obtained, a set of corresponding concentration ratios, 
Coutlet/Cinlet, could then be calculated. These concentration ratios were the foundation in this 
study to estimate the deposition fraction of graphene nanoparticle in the human airways. The 
deposition fraction in this study is defined as the percentage (%) of the graphene 
nanoparticles deposited within a certain airway section to the total graphene nanoparticles 
that entered the entire airway replica.
In the nasal airway deposition experiments, inspiratory flow rates of 15, 30, and 43.5 L/min 
were used in the deposition study. These flow rates represent inhalation flow rates of 
workers from being at an at-ease status to having moderate workloads.(32) The Coutlet/Cinlet 
concentration ratios obtained by the SMPS from different experimental conditions can be 
directly used for calculating the nasal deposition fraction, Dnasal:
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In the oral-to-lung airway deposition experiments, an inspiratory flow rate of 43.5 L/min 
was used for the deposition study. The flow rate distribution in the oral-to-lung airway for 
this inspiratory flow rate has already been well defined elsewhere.(33) To estimate the oral 
airway graphene nanoparticle deposition fraction, the experimental procedure is similar to 
that of the nasal airway study since the oral airway only has one airway section and one 
outlet as the nasal airway. The way to estimate the deposition fraction in a certain lung 
bifurcation in the tracheobronchial airways of the oral-to-lung airway replica is depicted as 
follows: given that a lung bifurcation has one parent tube (p) and two daughter tubes (d1 and 
d2 for the left daughter tube and right daughter tube, respectively), the graphene nanoparticle 
deposition fraction in that lung bifurcation can be calculated by the equation derived from 
the principle of mass conservation: (19)
(2)
where Dlung is the deposition fraction (in percentage) of graphene nanoparticle in a certain 
lung bifurcation; Qp/Qoral, Qd1/Qoral, and Qd2/Qoral are respective flow rate ratios of the flow 
rate in the parent tube, left daughter tube, and right daughter tube with regarding to the total 
flow rate entering the oral airway (43.5 L/min in this study); Cp/Coral, Cd1/Coral, and Cd2/
Coral, are the graphene nanoparticle concentration ratios measured at the parent tube, left 
daughter tube, and right daughter tube, respectively (the Coutlet/Cinlet mentioned above). 
Here, since the total flow rate and the flow rate distribution in the tracheobronchial airways 
are already defined, the Qp/Qoral, Qd1/Qoral, and Qd2/Qoral in equation (2) are all known 
variables. Thus, to calculate the deposition fraction for the lung bifurcation, the only 
unknowns for solving equation (2) are those concentration ratios. Once the concentration 
ratios, Coutlet/Cinlet, are measured for each lung bifurcation on the oral-to-lung airway 
replica, the graphene nanoparticle deposition fraction in each lung bifurcation can be 
estimated, and a complete airway fractional deposition map can then be constructed. To 
facilitate measuring all necessary Coutlet/Cinlet on the oral-to-lung airway replica to calculate 
deposition fractions, the trimmed airway replicas shown in Figure 4 were made for this 
purpose. With these trimmed airway replicas, Coutlet/Cinlet for each lung tube on the oral-to-
lung airway replica can be obtained. Figure 7 summarizes the procedure of how to measure 
the Coutlet/Cinlet for size classified graphene nanoparticles, as well as the way to calculate the 
deposition fraction for a certain lung bifurcation. In this study, the Coutlet/Cinlet for each 
experimental condition (combined with different classification diameters, flow rates, and 
lung tube outlets) was measured at least three times for obtaining statistically meaningful 
results.
Also, in this study, graphene nanoparticle delivery loss due to diffusion deposition in the 
tubing system of the experimental setup was considered and thoroughly addressed. Separate 
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experiments were carried out by size classified NaCl nanoparticles with the same designated 
classification diameters as graphene nanoparticles for investigating the delivery efficiency of 
the experimental setup. From the investigation, a set of delivery efficiency correction factors 
(F) covering all experimental conditions and airway replicas in this study were acquired. The 
delivery efficiency correction factor, F, was then incorporated into the equation (1) and (2) to 
calculate the final airway deposition fraction: True concentration ratio = F × Measured 
concentration ratio. In this way, it is believed a more accurate graphene nanoparticle airway 
deposition can be achieved. For the sake of brevity, the experimental procedure and results 
regarding the investigation of the particle delivery efficiency correction factors are not 
repeated here; all of the details can be found in our previous works.(18, 19)
 RESULTS
Figure 8 shows the calculated aerodynamic diameter (dae) and effective density (ρeff) of the 
size classified graphene nanoparticle acquired from the DMA-APM tandem study. Figures 9 
and 10 display the fractional deposition map of size classified graphene nanoparticles in the 
human nasal airway and oral airway respectively. Figure 11a presents the nasal deposition 
efficiency of graphene nanoparticles as a function of impaction parameter dae2Q (Q is the 
flow rate in the airway). The impaction parameter is a common physical parameter used for 
presenting aerosol airway deposition data in irregular or complicated human airways such as 
nasal and oral airways. The deposition efficiency is defined as the ratio of graphene 
nanoparticles deposited within a certain airway section to the total graphene nanoparticles 
that entered that airway section. The deposition efficiency in any airway section of the 
airway replica can be calculated by the fractional deposition map data shown in Figures 9 
and 10. Also shown in Figure 11a are published data of nasal deposition efficiency acquired 
by using spherical particles.(27, 34, 35) Similarly, Figure 11b presents the graphene 
nanoparticle oral deposition efficiency as a function of impaction parameter together with 
published spherical particle data.(30) Figures 12a to 12c show the deposition efficiency in the 
tracheobronchial airways from the 1st to the 3rd lung generation. The deposition efficiencies 
were plotted against the Stokes number. The Stokes number for a particle in a lung 
bifurcation is expressed as Stk = ρo dae Us / 18ηD (ρo is the density of water, dae is displayed 
in Figure 8, Us is the mean air velocity in the parent tube, η is the air viscosity, and D is the 
mean diameter of the parent tube). The Stk is a dimensionless physical parameter frequently 
used for presenting aerosol deposition in the lung airways. Also shown in Figures 12 are 
deposition data of size classified NaCl particles obtained from this study, as well as other 
spherical particle data acquired previously from our laboratory.(17) It is worth noting that the 
spherical particle data shown in Figures 11 and 12 are for the purpose of data comparison, 
because all of these data were acquired from the same nasal and oral-to-lung airway replicas.
 DISCUSSION
As can be seen in Figure 2, the graphene nanoparticles could be ideally size classified by 
their dB. For each designated classification diameter (51, 101, or 215 nm), an apparent peak 
concentration was shown right at the channel bar corresponding to the designated 
classification diameter on the SMPS. This result implies that the majority of the graphene 
nanoparticles coming out of the DMA possessed the same dB, which can also be evidently 
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seen by the morphology of the graphene nanoparticles shown on the same figure. Therefore, 
in this study, the airway deposition data obtained from each classification diameter could be 
warranted to be generated by graphene nanoparticles with a same physical property, dB.
Also, from the graphene nanoparticle morphology presented in Figure 2, it is noticeable that 
the graphene nanoparticles were generally isometric in shape. The increase of the 
classification size made the particle diameter increase, but remained the particle morphology 
basically unchanged. When taking a close look at the graphene nanoparticle, it was found 
that the graphene nanoparticles are constructed by agglomerated graphene platelets. This 
might be due to the fact that all of the graphene nanoparticles were formed by evaporated 
graphene suspension droplets. The evaporation of the alcohol portion in a graphene 
suspension droplet will result in droplet shrinking and inside graphene nanoplatelet 
agglomerating, which eventually forms the particle morphology presented. A field sampling 
study conducted at a graphene manufactory also indicated that graphene aerosols released in 
the workplaces was primarily graphene agglomerates.(14) Therefore, the use of size 
classified graphene nanoparticles in the form of agglomeration for airway deposition 
experiments in this study is considered realistic and also practical to a certain extent. It is 
widely accepted that graphene agglomerates, once deposited in the lung airways, will 
gradually disperse in the lung mucus where the onset of graphene platelets nanotoxicity 
effects found in those in vivo and in vitro studies can then be seen.
Figure 8 indicates that the effective density, ρeff, of the size classified graphene nanoparticle 
was less than 1 g/cm3 in general (the density of carbon: ~2.0 g/cm3) and decreased as the 
designated classification diameter increased. This result implies that agglomerated graphene 
nanoparticles generated in this study contain a considerable portion of empty space within 
(lossed structure). The larger the particle size, the larger the portion of empty space. This 
phenomenon is in agreement with what was found in other published research on aggregate 
nanoparticles and nanofibers.(23, 36) Based on these ρeff acquired, the calculated dae for 
corresponding size classified graphene nanoparticles at 51, 101, 215 nm was found to be 47, 
84, 167 nm respectively.
The graphene nanoparticle fractional deposition map shown in Figures 9 and 10 indicate that 
the deposition of graphene nanoparticles in airway replicas was generally low and expressed 
basically no appreciable difference between different classification diameters. It can be seen 
that the deposition fractions were generally less than 4% in all airway sections examined in 
this study, and no apparent deposition pattern and trend was shown regarding the location in 
the oral-to-lung airway replica. In the nasal airway, the deposition fraction ranged from 1.3% 
to 2.4%. In the oral-to-lung airway, a considerable fraction of the graphene nanoparticles 
were found to deposit in the oral airway (1.7% to 3.1%) due to the fact that the oral airway 
(from the oral cavity to the larynx) contains a relatively larger total surface area for the 
graphene nanoparticle to deposit. In the tracheobronchial airways, the deposition fractions 
were found generally less than 1% from the 2nd to the 4th lung generations. The total 
fraction of the graphene nanoparticle deposited in the nasal and oral-to-lung airways 
together was around 10%. These results reveal that nearly 90% of the graphene 
nanoparticles (with the diameter studied in this research) inhaled into the human airway 
could easily penetrate through to the human upper airways.
Su et al. Page 8













Figures 11 and 12 express that the deposition efficiency of graphene nanoparticles in the 
human airways were generally less than 0.03. Published studies in literature also reported 
similar deposition results for ultrafine particles having close diameters as seen in this 
study.(15, 16) The low deposition efficiencies shown here prove again that most of the 
graphene nanoparticles entering into the human respiratory tract can easily penetrate through 
airway sections in the upper airways. When comparing the deposition efficiencies of 
graphene nanoparticles to those of NaCl particles, it can be seen that all of the data points 
were scattered and showed no significant discrepancy between different data sets. Moreover, 
it can be seen in Figure 12 that data points were well connected between the nano-scale 
group (three sizes from 51 to 215nm) and the micro-scale group (eight sizes from 0.98 to 30 
μm) forming a smooth data trend. The trend of the deposition efficiency reveals a well-
recognized aerosol airway deposition characteristic: particles in the micro-scale show an 
increase of the deposition efficiency proportionally to the increase of the particle inertia. The 
airway deposition mechanism for these micro-scale particles is inertia impaction. On the 
other hand, particles in the nano-scale as studied in this research hold low particle inertia, 
their deposition efficiencies in the airway are low, and the deposition mechanism of these 
nano-scale particles in the airway should be Brownian diffusion.
Based on all of the deposition results acquired from this study, it is reasonable to summarize 
that, in the range of the nanoparticle diameter studied in this research (around 50 to 200 nm), 
even though the morphology of the nanoparticles are various (such as graphene 
nanoparticles vs. NaCl nanoparticles), as long as they possess a similar dB, their dae won't be 
discrepant significantly, which will result in a similar aerodynamic behavior and comparable 
deposition efficiency in the airway. Also, it was clearly shown in this study that the inhaled 
graphene nanoparticles can easily pass through the human nasal, oral, and upper portion of 
the tracheobronchial airways. Therefore, worker exposure to graphene nanoparticles in 
related graphene manufacturing workplaces could result in a considerable amount of 
graphene nanoparticles entering in the lower airways, where adverse health effects could 
possibly be induced.
 CONCLUSION
The inhalation and deposition of airborne graphene nanoparticles in the human airways 
could cause possible adverse health effects to workers in graphene nanomaterial related 
workplaces. Studying the deposition of graphene nanoparticles in the human airway, 
therefore, is very important from the viewpoint of occupational health. In this study, 
graphene nanoparticles were generated, size classified, and delivered into human airway 
replicas for airway deposition experiments using a novel experimental approach. The 
fractional deposition map obtained from this study showed that the graphene nanoparticle 
deposition in the studied airway sections were all less than 4%, and the deposition efficiency 
in each airway section was generally lower than 0.03. This result implies that most of the 
graphene nanoparticles inhaled into the respiratory tract would enter the lower 
tracheobronchial airways, where potential health effects might be induced. Moreover, it was 
found that nanoparticles having similar dB will behave similarly in the airway, which will 
result in comparable deposition efficiencies in airways. The experimental approach 
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employed in this deposition study proved to be a desired experimental method for carrying 
out airway deposition study using size classified nanoparticles.
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The morphology of the graphene nanomaterial used in this airway deposition study.
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The morphology of the size classified graphene nanoparticles, size distribution measured by 
SMPS, and the area equivalent diameter calculated from the particle envelop area (a) 51 nm, 
(b) 101 nm, and (c) 215 nm (CGMD = count geometric median diameter; σg = geometric 
standard deviation; particle reference bars in each subpicture represents 200 nm).
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The schematic of the human nasal airway replica.
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The schematic of the human oral-to-lung airway replica and the trimmed replicas.
Su et al. Page 15














The experimental setup of graphene nanoparticle nasal airway deposition study.
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The experimental setup of graphene nanoparticle oral-to-lung airway deposition study.
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The procedure of the measurement and calculation for graphene nanoparticle concentration 
ratio.
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The effective density and the aerodynamic diameter of the size classified graphene 
nanoparticles as a function of the classification diameter (electrical mobility diameter).
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The deposition fraction of size classified graphene nanoparticles in the nasal airway.
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Fractional deposition maps of size classified graphene nanoparticles in the human 
respiratory tract replica.
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The deposition efficiency of graphene nanoparticles in (a) nasal airway, and (b) oral airway 
as a function of the impaction parameter.
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The deposition efficiency of graphene nanoparticles in the human tracheobronchial airways 
as a function of the Stokes number (a) 1st lung generation, (b) 2nd lung generation, and (c) 
3rd lung generation.
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